SURPASS was a head-to-head study comparing SEC vs ADA biosimilar (SDZ-ADL) in r-axSpA on spinal radio progression: Results showed no significant diff in spinal radio progression bet. the 2 grps. Biosimilars remain tx options for r-axSpA. #ACR22 @RheumNow ABST#L15